Journal of Hepatocellular Carcinoma最新文献

{"title":"FAM105B Promotes Hepatocellular Carcinoma Progression and Metastasis by Activating the PI3K/AKT/MTOR Signaling Pathway and Inducing Epithelial-Mesenchymal Transition.","authors":"Liu-Lin Yang, Xing Chen, Shao-Tong Tang, Kai-Ting Huang, Gui-Yan Ye, Ji-Long Wang","doi":"10.2147/JHC.S519954","DOIUrl":"10.2147/JHC.S519954","url":null,"abstract":"<p><strong>Background: </strong>Recurrence and metastasis are major contributors to poor prognosis in hepatocellular carcinoma (HCC), yet the mechanisms remain unclear. FAM105B, a specific deubiquitinating enzyme, is critical in various biological processes, including cancer progression. However, its role in HCC is not well understood.</p><p><strong>Methods: </strong>FAM105B expression in HCC patients was validated using public clinical datasets. Cox regression and Kaplan-Meier analyses assessed its association with clinicopathological features and prognosis. In vitro and in vivo experiments evaluated the effects of FAM105B on HCC cell proliferation and invasion. Its role in epithelial-mesenchymal transition (EMT) and the PI3K/AKT/MTOR pathway was analyzed via, Western blot, Reverse Transcription Quantitative Polymerase Chain Reaction (qRT-PCR), immunohistochemistry and immunofluorescence.</p><p><strong>Results: </strong>FAM105B was significantly upregulated in HCC tissues and cell lines. High FAM105B expression correlated with aggressive features and poorer overall survival (OS) and disease-free survival (DFS). Functional studies revealed that FAM105B overexpression promoted, while knockdown inhibited, HCC cell proliferation and invasion. Mechanistically, FAM105B induced EMT and activated the PI3K/AKT/MTOR pathway.</p><p><strong>Conclusion: </strong>FAM105B promotes HCC progression by inducing EMT and activating the PI3K/AKT/MTOR pathway, highlighting its potential as a therapeutic target and prognostic biomarker.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1541-1555"},"PeriodicalIF":3.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Autophagy-Related Gene Expression in Hepatocellular Carcinoma via TCGA, GEPIA2, and HPA Databases: Implications for Prognosis.","authors":"Xiangran Gu, Yuan Chen, Xinyue Hu, Yunhui Li, Renlong Zhu, Hongxu Li, Zhengrong Yuan, Yajie Wang","doi":"10.2147/JHC.S520917","DOIUrl":"10.2147/JHC.S520917","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify autophagy-related genes (ARGs) with prognostic significance in hepatocellular carcinoma (HCC) using bioinformatics and survival analysis.</p><p><strong>Materials and methods: </strong>ARGs were sourced from multiple references, including the Human Autophagy Database (HADb), relevant literatures, the Gene Set Enrichment Analysis (GSEA), and a final list was confirmed after eliminating duplicate entries. Differential expression analysis between normal and tumor tissues relied on data from The Cancer Genome Atlas (TCGA). Subsequently, the univariate and multivariate Cox regression analysis, along with the Kaplan-Meier survival analysis, were conducted to identify survival-associated genes. These findings were cross-validated using the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database and the Human Protein Atlas (HPA) database. Furthermore, expression levels of randomly selected ARGs were validated in HCC and normal cell lines using Real-time quantitative PCR (RT-qPCR), confirming bioinformatics findings.</p><p><strong>Results: </strong>41 ARGs were pinpointed. The bioinformatics analysis revealed elevated expression levels of these genes in HCC tissues compared to normal tissues. Notably, mRNA expression levels of ARGs were markedly higher in the tumor tissue samples than in the normal liver tissue samples. This observation was corroborated by data from the GEPIA2 and HPA databases, except for <i>ATG4B</i> and <i>CAPN10</i>. Results from the HPA database aligned with those from the TCGA analysis. GSEA uncovered potential signaling pathways associated with ARGs, including pathways relevant to cancer and autophagy. RT-qPCR analysis further confirmed significant upregulation of mRNA expression levels of randomly selected <i>BAG3, EIF2AK2, KIF5B</i>, and <i>RAB24</i> in HCC cell lines, consistent with the bioinformatics analysis findings.</p><p><strong>Conclusion: </strong>This study showed that the 41 obtained ARGs, such as <i>ATG16L1</i>, <i>ATG4B</i>, <i>BAG3</i>, <i>KIF5B</i>, <i>MAPK1</i>, <i>RAB24</i>, and <i>SOGA1</i>, these findings suggest that ARGs may serve as prognostic biomarkers for HCC, warranting further validation in clinical cohorts and functional studies.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1557-1586"},"PeriodicalIF":3.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.","authors":"Caiyun Lu, Renming Liu, Yanyang Zhang, Junyang Luo, Cheng Luo, Zaibo Jiang, Mingsheng Huang, Chunhui Qiu, Junwei Chen","doi":"10.2147/JHC.S517855","DOIUrl":"10.2147/JHC.S517855","url":null,"abstract":"<p><strong>Background: </strong>Transarterial chemoembolization (TACE) combined with Lenvatinib plus programmed death-1 inhibitor (PD-1 inhibitor) is recommended for unresectable hepatocellular carcinoma (uHCC), and it has increased the probability of successful conversion. Our aim was to compare the clinical benefits of TACE combined with Lenvatinib-PD-1 inhibitor versus TACE monotherapy as conversion therapy for patients with uHCC who subsequently underwent liver resection (LR).</p><p><strong>Materials and methods: </strong>This retrospective study included 213 uHCC patients who underwent LR after receiving either TACE combined with Lenvatinib plus PD-1 inhibitor (combination group, n=109) or TACE monotherapy (monotherapy group, n=104). Propensity score matching was employed to minimize baseline confounding variables between cohorts. Tumor response, disease-free survival (DFS), overall survival (OS), and adverse events (AEs) were assessed between treatment arms.</p><p><strong>Results: </strong>Among 68 matched pairs of patients who underwent LR, only 1 patient developed small-for-size syndrome. The combination group demonstrated superior treatment responses compared with the monotherapy group, with a significantly higher objective response rate (92.65% vs 80.88%, <i>p=0.043</i>) and pathological complete response rate (36.76% vs 11.76%, <i>p<0.001</i>). Furthermore, histopathological analyses revealed a lower incidence of microvascular invasion in the combination group compared with the monotherapy group (14.71% vs 29.41%, <i>p=0.039</i>). Survival analyses demonstrated significantly improved DFS (median not reached vs 20.0 months, <i>p=0.002</i>) and OS (median not reached for both, <i>p=0.005</i>) in the combination group. Multivariate Cox proportional hazards regression identified preoperative monotherapy as an independent adverse prognostic factor for both DFS (HR, 2.46) and OS (HR, 3.05). Although combination therapy showed superior therapeutic efficacy, it was linked to a significantly higher incidence of rash and hand-foot skin reactions.</p><p><strong>Conclusion: </strong>Compared to TACE monotherapy, TACE combined with Lenvatinib-PD-1 inhibitor as conversion therapy can improve long-term survival outcomes in patients with uHCC who undergo subsequent LR, with an acceptable safety profile.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1527-1540"},"PeriodicalIF":3.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-Based Quantification of Enhancing Tumor Volume on Contrast-Enhanced MRI to Predict Pathologic Response and Prognosis in HCC After HAIC Plus Targeted Therapy and Immunotherapy.","authors":"Yin Zhou, Junjie Li, Qingshu Li, Liu Liu, Ping Huang, Yun Mao, Yaying Yang, Furong Lv, Ziyu Liu","doi":"10.2147/JHC.S527789","DOIUrl":"10.2147/JHC.S527789","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the diagnostic and prognostic value of AI-quantified MRI tumor volume for assessing pathologic response in unresectable hepatocellular carcinoma (uHCC) after hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy (HAIC-TI).</p><p><strong>Materials and methods: </strong>This retrospective study included 35 patients (46 lesions) who underwent HAIC-TI followed by hepatectomy. AI was used to calculate the tumor enhancement volume ratio (TEVR) from MRI. Correlation analysis was conducted to evaluate the relationship between TEVR and pathological tissue proportions. Receiver operating characteristic (ROC) curve determined the optimal cutoff for the ratio of viable tumor cells (RVTCs) to define major pathological response (MPR). The diagnostic performance of AI for MPR and its prognostic significance in recurrence-free survival (RFS) were assessed.</p><p><strong>Results: </strong>TEVR in portal venous phase is strongly correlated with non-necrotic tissue ratio (r = 0.89, <i>p</i> < 0.001). RVTCs ≤ 10% predicted reduced intrahepatic recurrence (Area Under the Curve [AUC] = 0.808, <i>p</i> < 0.001) and independently associated with prolonged RFS (HR [hazard ratio] = 0.19, 95% CI [confidence interval]: 0.05-0.69, <i>p</i> = 0.011). TEVR ≤ 19.5% in the portal venous phase demonstrated high diagnostic performance for identifying MPR (AUC = 0.879) and was significantly associated with improved RFS in both univariable analysis (HR = 0.34, 95% CI: 0.12-1.00, <i>p</i> = 0.049) and the multivariable model incorporating only clinical and imaging factors.</p><p><strong>Conclusion: </strong>AI-based MRI quantification of TEVR effectively reflected pathologic response and served as a non-invasive prognostic marker for postoperative recurrence in uHCC patients after HAIC-TI.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1509-1525"},"PeriodicalIF":3.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Benefit of Adjuvant Treatment with Huaier Granules Plus Lenvatinib in Hepatocellular Carcinoma Patients with Tumors Greater Than 5 cm After Radical Hepatectomy.","authors":"Cong Liu, Ying Bai, Qingquan Bai, Maria A Parra, Liangliang Zhao, Jiashu Zou, Qian Cao, Haoling Liu, Haiyan Yang","doi":"10.2147/JHC.S515730","DOIUrl":"10.2147/JHC.S515730","url":null,"abstract":"<p><strong>Background: </strong>The postoperative recurrence of hepatocellular carcinoma (HCC), influenced by various factors, including microvascular invasion (MVI), plays a critical role in the long-term prognosis following radical liver resection. This study investigated potential adjuvant treatment strategies for HCC patients who exhibit multiple recurrence factors after radical resection.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on data from 243 patients who underwent radical resection for HCC and exhibited high recurrence factors at the First Affiliated Hospital of Harbin Medical University. Some of these patients received postoperative adjuvant therapy with Huaier granules, lenvatinib, or a combination of both, while others did not receive any postoperative adjuvant therapy.</p><p><strong>Results: </strong>Survival analysis showed a more favorable prognosis in the adjuvant Huaier granules and lenvatinib groups (all P < 0.05). Furthermore, when compared to monotherapy, the combination therapy group exhibited significantly improved overall survival (OS) (P = 0.001) and disease-free survival (DFS) (P = 0.001). Multivariate Cox regression analysis demonstrated that the addition of Huaier granules to lenvatinib was an independent protective factor associated with improved OS (hazard ratio (HR) = 0.777, 95% confidence interval (CI) = 0.616-0.980, P = 0.033) and DFS (HR = 0.753, 95% CI = 0.615-0.920, P = 0.006).</p><p><strong>Conclusion: </strong>In this retrospective analysis, the combination of Huaier granules and lenvatinib as postoperative adjuvant therapy was associated with improved long-term prognosis in patients at high risk of HCC recurrence.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1495-1507"},"PeriodicalIF":3.4,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Gd-BOPTA Enhanced MRI in Solitary Resected Hepatocellular Carcinoma Without Microvascular Invasion.","authors":"Juan Zhang, Hongmei Luo, Yinqiao Li, Yayuan Feng, Xingpeng Pan, Beilei Ouyang, Guihong Nian, Ningyang Jia, Yonggang Li","doi":"10.2147/JHC.S530701","DOIUrl":"10.2147/JHC.S530701","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the prognostic predictive efficacy of Gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) in patients with solitary hepatocellular carcinoma (HCC) without microvascular invasion (MVI) and to investigate the potential clinical and imaging parameters for stratifying the risk of recurrence following hepatectomy.</p><p><strong>Methods: </strong>This retrospective study included 134 patients with histopathologically confirmed solitary HCC without microvascular invasion (MVI) from two hospital districts, which divided into the training cohort and validation cohort. MRI features were independently assessed by two radiologists. Univariate and multivariate Cox regression analyses were conducted to identify independent risk factors associated with recurrence-free survival (RFS). A nomogram was developed based on these factors, and its performance was validated in the validation cohort. RFS was analyzed using Kaplan-Meier curves and the Log rank test.</p><p><strong>Results: </strong>The median RFS for the 134 patients was 45.7 months, with 41.8% of patients experiencing tumor recurrence after hepatectomy. Univariate Cox regression analysis identified hepatitis Be antigen (HBeAg) positivity, tumor size, tumor growth subtype, non-peripheral washout, nodule-in-nodule architecture, mosaic architecture, and intratumoral arteries as significant risk factors for RFS. Multivariate Cox regression analysis revealed that HBeAg positive, tumor growth subtype, non-peripheral washout, mosaic architecture, and internal arteries were independent prognostic factors for RFS in patients with solitary HCC without MVI. The nomogram based on these variables demonstrated good predictive accuracy, with concordance indices (C-index) of 0.740 and 0.701 in the training and validation cohorts, respectively. Additionally, patients in the high-risk group exhibited significantly lower RFS compared to those in the low-risk group.</p><p><strong>Conclusion: </strong>A model incorporating Gd-BOPTA-enhanced MRI and clinical features can effectively predict RFS in solitary HCC patients without MVI and assist in risk stratification for recurrence after hepatectomy.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1471-1482"},"PeriodicalIF":4.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12282532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Liver Imaging Score to Predict Clinically Significant PHLF for Hepatocellular Carcinoma After Resection.","authors":"Xihua Zheng, Yumin Zhang, Huiying Huang, Ningbin Luo","doi":"10.2147/JHC.S511240","DOIUrl":"10.2147/JHC.S511240","url":null,"abstract":"<p><strong>Purpose: </strong>To develop a model based on Functional Liver Imaging Score (FLIS) to estimate the risk of clinically significant post-hepatectomy liver failure (PHLF) for hepatocellular carcinoma (HCC) after resection.</p><p><strong>Patients and methods: </strong>This retrospective study analyzed 885 patients with HCC who undergoing liver resection at our medical center between January 2017 and December 2021. Patients were randomly (7:3) assigned to development (n=620) or internal validation (n=265) cohorts. Univariable and multivariable logistic regression analyses were performed to identify independent risk factors for clinically significant PHLF, defined as grade B or C PHLF by the International Study Group of Liver Surgery. Predictive performance was assessed by the area under receiver operator characteristic curves (AUC).</p><p><strong>Results: </strong>Clinically significant PHLF occurred in 7.7% of the development cohort and 7.2% of the internal validation cohort. Multivariate analysis identified FLIS, major resection and ALBI score as independent predictors of clinically significant PHLF, and a model combining these three variables predicted failure in the development cohort (AUC 0.746, 95% CI 0.673-0.820) and internal validation cohort (AUC 0.717, 95% CI 0.595-0.838). The same model also predicted mortality within 90 days after surgery in the development cohort (AUC 0.704, 95% CI 0.575-0.832) and internal validation cohort (AUC 0.717, 95% CI 0.586-0.848). In both cohorts, overall survival rate was significantly lower among patients whom the model placed at high risk of clinically significant PHLF than among those at low risk.</p><p><strong>Conclusion: </strong>The combination of FLIS and other easily acquired clinical data may reliably predict clinically significant PHLF and mortality in hepatocellular carcinoma.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1483-1493"},"PeriodicalIF":4.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Multi-Omics Profiling Identifies PDZ-Binding Kinase (PBK) as a Novel Prognostic Biomarker in Hepatocellular Carcinoma.","authors":"Juan Zhang, Yingyu Xu, Xiaojian Ni, Zhiyi Mao, Haitao Xiao, Maopei Chen, Youpei Lin, Jiaomeng Pan, Boheng Zhang, Lan Zhang, Xueying Zheng, Guohe Song, Ningling Ge","doi":"10.2147/JHC.S493907","DOIUrl":"10.2147/JHC.S493907","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) necessitates novel immunotherapeutic targets. PBK, a cancer/testis antigen (CTA), was identified as a pivotal hub gene influencing prognosis, tumor mutation burden (TMB), and immune microenvironment remodeling.</p><p><strong>Methods: </strong>PBK was prioritized using weighted gene co-expression network analysis (WGCNA) and differential expression screening in the TCGA-LIHC cohort, intersected with curated CTAs. Analyses assessed correlations with clinicopathological features (TNM stage, survival), genomic characterization (mutation frequencies), and functional validation via siRNA-mediated PBK knockdown in Huh7 cells (migration assay). Single-cell RNA sequencing (scRNA-seq) profiled of the tumor immune microenvironment.</p><p><strong>Results: </strong>PBK overexpression was significantly correlated with advanced TNM stage (<i>P</i> < 0.05) and poor survival (log-rank <i>P</i> = 0.003). Genomic analysis revealed distinct mutation profiles: high-PBK tumors exhibited increased <i>TP53</i> mutation frequency (39% vs 17%) but decreased <i>CTNNB1</i> mutations (20% vs 31%). Patients exhibiting with combined PBK overexpression and high TMB demonstrated the poorest prognosis. Functional validation confirmed that PBK knockdown significantly inhibited Huh7 cell migration capacity (<i>P</i> < 0.05). scRNA-seq analysis showed PBK-enriched tumors contained elevated proportions of immunosuppressive SPP1(+) macrophages (22.33% vs 6.6%, FDR corrected <i>P</i> < 0.001) and CD8(+) SLC4A10(+) MAIT cells (9.82% vs 4.7%, FDR corrected <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>PBK synergistically drives HCC progression through three synergistic mechanisms: (1) promoting oncogenic mutation accumulation (eg, <i>TP53</i>), (2) increasing metastatic potential, and (3) reprogramming an immune-suppressive microenvironment enriched for SPP1(+) macrophages and CD8(+)SLC4A10(+) MAIT cells. This establishes PBK as a dual-purpose biomarker for prognostic stratification and immunotherapy resistance prediction, providing a mechanistic rationale for developing PBK-targeted therapies in HCC.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1453-1469"},"PeriodicalIF":4.2,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma.","authors":"Yangshuo Xia, Wu Wen, Yangyu Liao, Yingxiao Cai, Renhua Wan","doi":"10.2147/JHC.S510814","DOIUrl":"10.2147/JHC.S510814","url":null,"abstract":"<p><strong>Purpose: </strong>HCC exhibits a high postoperative recurrence rate, with early recurrence (≤2 years) accounting for 70% of cases, predominantly associated with high-risk recurrence factors. Common adjuvant therapies for HCC include postoperative adjuvant hepatic arterial infusion chemotherapy (PA-HAIC) and postoperative adjuvant transarterial chemoembolization (PA-TACE). This study evaluates the comparative efficacy and safety of PA-HAIC versus PA-TACE in preventing early recurrence among HCC patients with postoperative high-risk recurrence factors.</p><p><strong>Patients and methods: </strong>A retrospective analysis included 170 HCC patients with high-risk recurrence factors following surgical resection (2018-2023), divided into PA-HAIC (n=23) and PA-TACE (n=147) groups. To mitigate potential biases and adjust for baseline characteristics, propensity score matching (PSM) was performed. Survival analyses for two primary endpoints, recurrence-free survival (RFS) and overall survival (OS), were then conducted using the Kaplan-Meier method and Cox proportional hazards regression. Adverse event (AE) rates and severity were compared.</p><p><strong>Results: </strong>Post-PSM analysis revealed significantly superior RFS rates in the PA-HAIC group versus PA-TACE at 6,12,and 24 months (100%, 95.7%, 95.7% vs 91.3%, 73.9%, 65.2%;p=0.0085). Multivariable Cox regression identified PA-HAIC (HR=0.20, 95% CI:0.02-0.71;p=0.020) and intact tumor capsule (HR=0.02, 95% CI:0.00-0.41;p=0.011) as independent protective factors for RFS, while vascular tumor thrombus (HR=28.02, 95% CI:2.07-378.81;p=0.012) emerged as a risk factor. Subgroup analyses identified age ≥50 years, solitary tumors, BCLC-A stage, absence of MVI, intact capsule, and no vascular thrombus as low-risk factors for early recurrence. Safety profiles showed no significant between-group differences in AE incidence or severity.</p><p><strong>Conclusion: </strong>Among HCC patients with high-risk recurrence factors after surgical resection, PA-HAIC demonstrated significantly prolonged RFS compared to PA-TACE, with a favorable safety profile.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1425-1439"},"PeriodicalIF":4.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Summary of the HCC-CARE Symposium: Collaborative Approaches to Reaching Equity in Hepatocellular Carcinoma in Boston by 2030.","authors":"Kelsey S Lau-Min, Thomas Abrams, Andrea Bullock, Alyson Kaplan, Leslie Salas Karnes, Mark W Kennedy, Christina A LeBedis, Ming V Lin, Nadine Jackson McCleary, Shirin Sioshansi, Emma Voligny, Elizabeth Paige Walsh, Christopher R Manz","doi":"10.2147/JHC.S528033","DOIUrl":"10.2147/JHC.S528033","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality in the United States. Disparities in HCC incidence and mortality are amplified in Boston, Massachusetts, which has 42% higher HCC mortality than the nation. HCC-CARE was a one-day symposium that aimed to identify goals and strategies necessary to eliminate HCC disparities in the Greater Boston area by 2030. Sixty-six local and state stakeholders attended the symposium, including HCC clinical experts (eg, medical oncologists) and primary care clinicians representing all seven of Boston's major cancer centers, ancillary staff members (eg, social workers) and state and local government agencies. The symposium included introductory sessions on HCC disparities, conceptual approaches to addressing disparities, and perspectives of local stakeholders on HCC disparities, followed by two interactive workshops where nine groups brainstormed and voted on goals, then developed preliminary action plans. Symposium participants identified four priority goals and developed associated action plans to eliminate HCC disparities by 2030: 1) improving HCC screening rates to enable early detection, 2) employing community engagement and outreach to communities at high risk of HCC, 3) developing a multi-institutional HCC registry to inform care delivery improvements, and 4) connecting patients with HCC to support services to address common barriers to care. A fifth priority around addressing disparities in HCC treatment emerged from post-symposium feedback. HCC-CARE established a knowledge base and raised the saliency of HCC disparities among participants, created a multi-institutional consortium of individuals committed to addressing HCC disparities, and leveraged the wide-ranging expertise of the participants to identify key goals and strategies for achieving equity in HCC outcomes by 2030. These strategies require further development and implementation through multi-institutional committees established after the symposium for each priority area. The Symposium represented a key first step in launching coordinated efforts to reduce HCC disparities that other cities may emulate.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1417-1424"},"PeriodicalIF":3.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}